ArticleFrontiers in oncology2026
Ovarian dose prediction after ovarian transposition in cervical cancer: comparing three models and the impact of geometric distance on predictive performance.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare three models for predicting mean ovarian dose after ovarian transposition in cervical cancer patients and identify geometric factors affecting prediction reliability. Methods: We analyzed 100 ovaries from 51 patients using three models: a log-linear model (dose vs. distance), a random forest (RF) incorporating multiple geometric features, and a 3D U-Net for voxel-wise dose prediction. Models were validated using patient-wise 5-fold cross-validation. Accuracy was assessed by mean absolute error (MAE), median absolute error (MedAE), root mean square error, tolerance rates, and Bland-Altman analysis. A sliding-window residual standard deviation curve determined the distance at which prediction uncertainty increased, with subgroup analyses performed accordingly. Results: RF achieved the lowest MAE (0.803 Gy) and MedAE (0.365 Gy), followed by the log-linear model (MAE: 0.886 Gy) and 3D U-Net (MAE: 0.890 Gy). The log-linear model showed the narrowest limits of agreement, suggesting greater stability. At ±0.5 Gy tolerance, RF significantly outperformed the log-linear model in our cohort (59% vs. 41%, Conclusion: 3D U-Net underperformed with limited data, whereas RF, with the lowest MAE, offered a practical alternative; the log-linear model showed the narrowest LoA, suggesting greater stability. All models showed substantially reduced predictive performance below 17 mm, where manual planning should take priority. This threshold may serve as an alert for performance degradation, but external validation is required before clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.